Influenza Diagnostics Market
Influenza Diagnostics Market Analysis By Test (Traditional Influenza Diagnostic Tests, Molecular Influenza Diagnostic Tests), By End User, By Region - Global Insights 2021 to 2031
Market Outlook for Influenza Diagnostics
Fact.MR’s influenza diagnostics industry analysis shows that global market reached a valuation of US$ 2.5 Bn in 2020, and is anticipated to top US$ 4 Bn by 2031, expanding at a CAGR of 5%. Demand for rapid influenza diagnostic testing (RIDT) is projected to reach a valuation of US$ 2 Bn by 2031, surging at a CAGR of 6%, while that for RT-PCR is set to increase at 5%.
Key Points Covered in Influenza Diagnostics Industry Survey:
- Market Estimates and Forecasts (2016-2031)
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- COVID-19 Impact on Demand for Influenza Diagnostics and How to Navigate
- Recommendation on Key Winning Strategies
Revenue Analysis of Influenza Diagnostics from 2016 to 2020 Vs Demand Outlook for 2021 to 2031
As per the influenza diagnostics industry research by Fact.MR – a market research and competitive intelligence provider, from 2016 to 2020, market value expanded at 4% CAGR, where North America, Europe, and Asia Pacific held a significant share in the global market.
Influenza, commonly known as 'the flu', is an infectious disease caused by an influenza virus. Various traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Nowadays, advanced technologies provide highly effective and accurate diagnosis of the influenza.
For instance, reverse transcription-polymerase chain reaction (RT-PCR), or real time, molecular test provides detection of influenza genetic material. Moreover, continued advancements in rapid influenza diagnostic testing (RIDT) have made this method an effective one for diagnosis because of its fast results and ease of specimen collection.
Factors such as increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing are expected to propel the growth of the global market over the coming years.
An Adaptive Approach to Modern-day Research Needs
Will Growing Awareness Regarding Importance of Early Influenza Diagnosis Drive Market Growth?
Early diagnosis of influenza leads to better treatment and care. It also helps medical professionals and patients take important medical decisions in terms of care and support. There exist a large number of advantages to obtain accurate and early diagnosis after noticing the cognitive symptoms related to a particular medical condition.
Laboratory examination is one of the very effective and popularly practiced testing techniques for the diagnosis of various infectious diseases associated with bacterial, viral, or protozoal infections. Immunoassays, biochemical characterization, polymerase chain reaction, isothermal nucleic acid amplification test, and next-generation sequencing are performed to identify a comprehensive range of infectious diseases.
Increasing awareness among the global population regarding the importance of early disease detection is a major factor responsible for the growth of the global market for influenza diagnostics. Owing to this, organizations are taking initiatives to promote early diagnosis practice to prevent and eradicate mortality due to the disease. For instance:
- In 2019, Public Health England (PHE) launched a 5-year (2020 to 2025) infectious disease strategy (which includes influenza) to prevent, detect, respond, and reduce the impact of infectious diseases.
- WHO designed the Global Influenza Strategy 2019-2030 with the goal of reducing the burden of seasonal influenza, minimizing the risk of zoonotic diseases, and mitigating the impact of the influenza pandemic.
Thus, rising concerns with regards to early diagnosis of influenza are accelerating the adoption of diagnostic products across the world.
Which Region Offers Great Potential for Influenza Diagnostic Manufacturers?
North America holds around 37% of the market share for influenza diagnostics.
However, the Asia Pacific market is expected to grow at a faster CAGR during the forecast period, mainly attributed to increasing influenza incidence, rising aging population, increasing focus of key vendors in the diagnostics market on this region, favourable reimbursement scenario for diagnostic procedures, increasing government investments to support the healthcare sector, improving infrastructure & accessibility to healthcare, and rising demand for better healthcare.
Why is the U.S a Growth Epicentre for Influenza Diagnostic Product Suppliers?
The U.S. market size was valued at US$ 685 Mn in 2020, and is anticipated to progress at a CAGR of 6% during the forecast period.
Rising geriatric population is anticipated to fuel market growth. The aging population is highly susceptible to various diseases as they are weak immunologically, and therefore are at higher risk of contracting influenza. This is indicative of the rising incidence in the geriatric population, necessitating diagnostic products.
Rise in government initiatives towards enabling diagnosis has facilitated easy access to over the counter (OTC) tests that are user friendly and aid in timely diagnosis.
- For instance, in 2018, the Biomedical Advanced Research and Development Authority (BARDA), a part of the U.S. Department of Health & Human Services, announced its partnership with Diassess Inc. and Cue Health, Inc. to develop testing kits for influenza diagnosis. These OTC products are intended solely for homecare settings facilitating concerned patients to test for the infection.
Why is Demand for RDIT High in the Market for Influenza Diagnostics?
RDIT held the largest market share in 2020 as this is easily available and user friendly, facilitating effective diagnosis. Additionally, WHO also recommends the use of RDIT for influenza diagnosis as this method is moderately complex, sensitive, specific, and accurate.
Why is RT-PCR Method Gaining High Importance in This Space?
The RT-PCR method delivers results faster in comparison to cell cultures, ranging from 2 minutes to less than 2 hours. This technique also aids in the identification of antiviral resistance. Advancements in these technologies are further expected to boost market growth during the forecast period.
For instance, Thermo Fisher Scientific Inc. offers QuantStudio 3 and 5 RT-PCR, which is simple and easy to use, and is designed for both, new and experienced users. QuantStudio 3 and 5 RT-PCR is combined with the Thermo Fisher Cloud platform that helps individuals to remotely monitor and access results, and also enables collaboration with colleagues anytime and anywhere.
Therefore, such technological advancements are anticipated to further fuel market growth during the assessment period.
What Has Been the Impact of COVID-19 on the Sales of Influenza Diagnostic Products?
Rising burden of infectious diseases across the globe has increased the demand for infectious disease diagnosis products, including influenza & other diseases. The recent outbreak of coronavirus (COVID-19) has caused disruptions in several countries across the world.
When compared to influenza, both viruses have a similar disease presentation, i.e., they both cause respiratory issues. Moreover, both are transmitted by contact, droplets, and fomites. At earlier stages, COVID-19 patients are misdiagnosed with influenza.
However, soon it was realized that factors such as immunity, age group, transmission rate, vaccination, & few others are drastically different in case of COVID-19 & influenza.
Thus, after realizing the difference between these two infections, demand for influenza kits normalized and the need for a comprehensive approach for diagnosis & treatment gained importance to combat the COVID-19 pandemic.
The market scenario for influenza diagnostics is highly competitive. Moreover, the advancements in technology and the innovations in developing the quick, precise, and low-cost diagnosis for diseases is the major aspect creating an opportunity for market players.
Hoffmann-La Roche AG (Switzerland) dominated the global market in 2019. The company operates in the market by providing molecular diagnostic kits for the detection of various strains of infection-causing agents.
The company’s strategic initiatives, such as obtaining Clinical Laboratory Improvement Amendments (CLIA) waiver approvals for its influenza assays and test kits, will help it in establishing its presence in various international markets. Also, its strong distribution network and geographic presence will result in growth opportunities for the company in future.
Influenza Diagnostics Market Report Scope
Historical Data Available for
|US$ Mn for Value & ‘000 Units for Volume|
Key Regions Covered
Key Market Segments Covered
|Key Market Segments Covered||
Key Companies Profiled
|Customization & Pricing||
Available upon Request
Interested to Procure The Data
Key Segments Covered in Influenza Diagnostics Industry Research
- Traditional Influenza Diagnostic Tests
- Rapid Influenza Diagnostic Tests (RIDTs
- Direct Fluorescent Antibody (DFA) Tests
- Viral Culture
- Serological Assays
- Molecular Influenza Diagnostic Tests
- Reverse Transcription Polymerase Chain Reaction (RT-PCR)
- Isothermal Nucleic Acid Amplification Tests (INAAT)
- Loop Mediated Isothermal-based Amplification Assays
- Transcription Mediated Isothermal-based Amplification Assays
- Transcription Mediated Isothermal-based Amplification Assays
- Traditional Influenza Diagnostic Tests
By End User
- Hospitals & Clinical Laboratories
- Diagnostic Reference Laboratories
- Academic/Research Institutes
- FAQs -
The global influenza diagnostics market is worth US$ 2.5 Bn, and is projected to top US$ 4 Bn by 2031-end.
Sales of influenza diagnostic products are set to expand at a CAGR of 5% during 2021-2031.
Increasing prevalence of influenza and growing awareness regarding early detection using specific diagnostic tests are driving demand for influenza diagnostics.
Prominent players operating in this market are Thermo Fisher Scientific, Hologic, Quidel Corporation, F. Hoffmann-La Roche AG, Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, and Meridian Bioscience.
North America accounts for 37% of revenue share for influenza diagnostics.
RDIT (rapid diagnostics influenza tests) hold the largest market as they are easily available and are also user friendly.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
Serological transplant diagnostics market is projected to expand at around 2.5% CAGR through 2031. R...
Get detailed analysis on the DNA probe based diagnostics market along with an assessment for the yea...
Ovarian Cancer Diagnostics Market is expected to grow at a CAGR of 7% during, 2021-2031. Sales of KR...